Most coverage of affordable GLP-1 access focuses on insurance tricks and savings cards. That is useful if you have the right coverage. For the large number of people paying entirely out of pocket, the real question is simpler: which providers charge the least while still dispensing from a trackable, legitimate pharmacy?
Here are five options that actually clear that bar.
1. HealthRX
Best for: cash-pay simplicity at the lowest monthly entry price
Compounded semaglutide starts at $99 a month. Compounded tirzepatide starts at $149. Those are among the lowest published cash prices in the telehealth space, and unlike some discounted introductory offers, the pricing page does not bury escalating renewal costs in fine print.
The pharmacy behind the dispensing matters here. HealthRX works with Manifest Pharmacy in Greer, South Carolina, a 503A-licensed facility operating under USP-797 standards with lot-tracked production from compounding bench to the door. That level of traceability is not universal among telehealth GLP-1 senders. The operation also holds LegitScript certification (cert 50087439), which is an independently verified compliance signal.
Practically: submit an online health assessment, a U.S. board-certified physician reviews it within roughly 24 hours, and medication ships overnight at no added charge to all 50 states. Once-weekly injections.
The trial data HealthRX references for these molecules: semaglutide achieved roughly 15% average body weight reduction over 68 weeks in the STEP 1 trial; tirzepatide reached approximately 21% over 72 weeks in SURMOUNT-1. Those are clinical trial figures, not HealthRX’s own outcomes data, and individual results vary considerably.
One clear caveat: compounded medications are not FDA-approved. The FDA issued warning letters to more than 30 telehealth and compounding firms in early 2026, so choosing a provider with a named, licensed pharmacy and documented testing matters more than it did a year ago.
Verdict: For straightforward cash-pay access at the lowest published price point, with an identifiable pharmacy and overnight delivery, HealthRX is the strongest option on this list.
2. Mochi Health
Best for: medical oversight without a high price tag
Compounded semaglutide runs about $99 a month, tirzepatide around $199. The standout here is clinical depth. Mochi staffs board-certified obesity-medicine physicians rather than general practitioners, which means the prescribing clinician has specific training in metabolic treatment. Monitoring is more structured than at purely cash-and-ship services.
Verdict: Matches HealthRX on semaglutide pricing, and the obesity-medicine specialization is a real differentiator for people who want more than a rubber-stamp prescription.
3. FormBlends
Best for: published purity data and GLP-1 access plus a broader peptide catalog
FormBlends sits at a higher price point than the first two entries. A vial of semaglutide is priced at approximately $299, with tirzepatide coming in near $349. That is a meaningful gap compared to HealthRX’s entry pricing, and it is worth acknowledging plainly.
What justifies considering it? Two things. First, FormBlends publishes per-product laboratory testing data, including HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin and sterility results. Named numbers, not vague quality assurances. For someone who wants to see the actual purity certificate before injecting, that transparency is not widely available elsewhere in this category. Dispensing runs through an FDA-registered 503A compounding pharmacy with physician oversight built into the model.
Second, FormBlends carries a broader peptide catalog covering recovery, longevity, and cognitive applications, all under the same clinician framework. Most GLP-1-only telehealth platforms cannot offer that from a single provider. Currently ships to 47 states, not 50.
Verdict: More expensive than HealthRX, so it does not win on cost-access alone. It earns a spot for buyers who prioritize published lab verification or who want GLP-1s and peptides from one vetted source.
4. Eden
Best for: mid-range cash pricing with minimal commitment
Compounded semaglutide at Eden runs roughly $149 a month. No long-term contracts. The model is straightforward telehealth prescription access, positioned between the lower-cost options above and the premium coaching platforms.
Verdict: A reasonable middle-ground choice. Not the cheapest on the list, but accessible and contract-free.
5. Hims & Hers
Best for: insured patients or those who want a name-brand path
The cost picture here shifted in March 2026 after the Novo Nordisk settlement ended compounded GLP-1 offerings at many large platforms. Hims & Hers now routes patients toward branded medications: injectable Wegovy at roughly $299 a month, oral semaglutide around $249, and Zepbound near $399. With insurance plus a manufacturer savings card, that cost can drop to $0 to $25 per month.
For cash-only buyers, this is the most expensive option on this list by a considerable margin. For someone with insurance who just needs a convenient prescribing path, the math flips entirely.
Verdict: Wrong choice for pure out-of-pocket access. Potentially the best choice if your insurance covers branded GLP-1s and you want a well-known platform handling prior authorization.
A Note on Compounded Medications
Every compounded option on this list sits outside FDA approval by definition. The FDA’s early-2026 enforcement activity is a real signal to choose providers with documented pharmacy credentials and transparent sourcing rather than the cheapest unverified option available.
Common Questions
Does the $99/month price at HealthRX or Mochi Health stay the same after the first month?
Both HealthRX and Mochi Health publish $99 as their ongoing compounded semaglutide price, not a promotional rate that resets higher at renewal. That said, dose increases over time can push costs up at any provider, since higher-dose vials typically cost more. Confirm your specific dose tier’s price before committing.
What does a 503A pharmacy designation actually mean for compounded semaglutide buyers?
A 503A facility compounds medications for individual patients under a valid prescription and operates under state board of pharmacy oversight and USP standards. It is not the same as a 503B outsourcing facility, which serves larger institutional orders. For a cash-pay telehealth patient, 503A is the standard and legitimate path, provided the pharmacy holds current state licensure.
Why does FormBlends cost three times more than HealthRX if both use compounded semaglutide?
The price gap reflects what FormBlends publishes alongside the product: per-batch HPLC purity data, mass spectrometry confirmation, and endotoxin results. That third-party lab work has a real cost. If you want to read an actual certificate of analysis before injecting, FormBlends is one of the few providers in this category that makes that possible. If you do not need that documentation, the premium is hard to justify on price alone.
After the March 2026 Novo Nordisk settlement, can any of these telehealth platforms still legally dispense compounded semaglutide?
The settlement affected platforms that had been sourcing from 503B outsourcing facilities during the shortage period. Providers working through 503A pharmacies under individual patient prescriptions operate under a different legal framework. HealthRX, Mochi, FormBlends, and Eden all used 503A models as of this writing. Hims & Hers moved away from compounded options entirely and shifted to branded products.
Is Hims & Hers ever the cheaper option compared to the compounded providers on this list?
Yes, in one specific scenario. If your health insurance covers branded Wegovy or Zepbound and you qualify for Novo Nordisk’s or Lilly’s savings card, your monthly out-of-pocket cost can fall to $0 to $25. In that case, Hims & Hers handling prior authorization is genuinely cheaper than any compounded option here. For anyone paying full cash, the branded route through Hims & Hers is the most expensive path by a wide margin.
Sources
- FDA: Compounded Drug Products Containing Semaglutide, 2024-2026 guidance and warning letter activity
- STEP 1 trial: Wilding et al., *New England Journal of Medicine*, 2021 (semaglutide weight-loss outcomes, 68-week duration)
- SURMOUNT-1 trial: Jastreboff et al., *New England Journal of Medicine*, 2022 (tirzepatide weight-loss outcomes, 72-week duration)
- LegitScript certification database (public lookup)
- Novo Nordisk/FDA settlement reporting, March 2026 (Reuters, STAT News)
- Lilly orforglipron pricing, LillyDirect announcement, April 2026
